Immuno-oncology company Targovax ASA (OSE:TRVX) revealed on Wednesday the receipt of the European patent that will protect its mutant-RAS specific neoantigen peptides, mutant RAS specific T cells and vaccines TG01 and TG02, for the treatment of cancer in combination with chemotherapies.
The European Patent, which has been assigned the no 3040320, has been awarded by the European Patent Office, with expiry until 6 May 2034, added the company.
According to the company, the proprietary mutant-RAS neoantigen vaccine platform is designed to treat patients with tumors harboring RAS mutations, which are a driving cause of cancer development and progression and is linked to poor prognosis. By inducing an anti-mutant-RAS specific immune response, TG01 and TG02 have the potential to delay disease progression and increase survival, with a favorable safety profile compared to chemotherapy and many other treatment options.
Under the company's recent Phase I/II clinical trial TG01-01 in resected pancreatic cancer with TG01 treatment in combination with the chemotherapeutic agent gemcitabine, the immune response was seen in 94% (30/32) of patients.
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
ELIAS Animal Health names new chief revenue officer
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval